Latest Biotechnology, Pharmaceutical and Healthcare News - Page: 3
Showing News Articles 51–75 of 90
Revascor™, Mesoblast’s proprietary Mesenchymal Precursor Cell (MPC) product for cardiovascular diseases, was safe and well-tolerated at all doses, with no clinically relevant immune responses to donor cells Revascor™ therapy significantly reduced cardiac mortality and major adverse cardiac events (MACE) in patients with congestive heart failure over a mean follow-up o...
Mesoblast to Host Conference Call to Discuss RevascorTM Data Presented at American Heart Association
Melbourne, Australia; 15 November 2011: Global regenerative medicine company, Mesoblast Limited (ASX: MSB; OTC ADR: MBLTY), will host an investor conference call and webcast on Tuesday 15 November 8:15am Australian EDT (Monday, 14 November 2011 at 4:15pm U.S. EST, 9:15pm UK) following the presentation of data from its congestive heart failure clinical trial from 9:15am to 9:25am U.S. EST at t...
PerkinElmer Targets Holistic Data Solutions
A series of acquisitions is expanding and refining the company’s focus, explains CSO Dan Marshak. November 15, 2011 | With its recent acquisitions of CambridgeSoft and Geospiza to name but two, PerkinElmer is signaling a new strategy that highlight...
NuMedii’s New Way to ‘De-Risk’ Drug Repositioning Work
Stanford University spin off relies on database to identify new drug uses. By Deborah Borfitz November 15, 2011 | A newly minted biotechnology company is offering to match the molecular genomic activity of previously approved medicines to that of kno...
An Inside Perspective on PAREXEL
One of the oldest clinical research organizations discusses technology and changes in the industry. November 15, 2011 | Mark Goldberg, PAREXEL’s chief operating officer, has been with the company since 1997 when he started the CRO’s medical imagi...
High childhood IQ linked to subsequent illicit drug use, research suggests
A high childhood IQ may be linked to subsequent illegal drug use, particularly among women, new research suggests.
Telephone-based therapy and exercise appear effective for reducing chronic widespread pain
Telephone-delivered cognitive behavioral therapy and an exercise program, both separately and combined, are associated with short-term positive outcomes for patients with chronic widespread pain, and may offer benefits for patients diagnosed with fibromyalgia, according to a new report.
November 14 2011: GE Healthcare has launched the His Capture Kit and NTA Reagent Kit for time saving and convenient capture of histidine-tagged ligands using Biacore systems. The new His Capture Kit comprises of an optimized protocol and the required reagents for capture by an anti-histidine antibody. Requiring minimum assay development, the kit works in conjunction with a carboxyl-derivatize...
Skeletal Biology and Medicine I
This Annals volume presents manuscripts stemming from the 4th New York Skeletal Biology and Medicine Conference, held at Mount Sinai School of Medicine in New York City on April 27–30, 2011.Volume 1237
North West Fund for Biomedical invest £100K in University-spin out and healthcare sensor firms
10 November 2011: The University of Salford’s first ever drug development spin-out company Onco-NX and Manchester-based Kanichi Research Services Ltd have secured investment from the North West Fund for Biomedical. Drug discovery spin-out company Onco-NX and Kanichi Research Services, which develops a bespoke range of sensors for the healthcare market, have each received £5...
10 November 2011 - London, UK - Verona Pharma plc (AIM: VRP.L), the biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, has successfully demonstrated in a Phase IIa RPL554 study bronchodilator effects in patients with chronic obstructive pulmonary disease (“COPD”). The pilot Phase IIa study was carried out by a world leadi...
Key Points Single injection of Mesoblast's proprietary allogeneic, or off-the-shelf, Mesenchymal Precursor Cells (MPCs) significantly lowered blood sugar levels for up to eight weeks in non-human primates with Type 2 diabetes A clear dose-dependent effect was seen, with the highest three MPC doses maintaining significantly reduced blood glucose levels after eight weeks compared w...
10 November 2011: Malvern, UK: Equipped with the novel Aero dry dispersion unit, the new Mastersizer 3000 particle size analyzer from Malvern Instruments now extends dry measurement to the widest possible range of sample types. The design of the Aero reflects state-of-the-art dry powder dispersion knowledge and enables users to measure materials from cement to coffee, cohesive minerals to fra...
Cambridge, UK – 9 November 2011 - Lab21 Limited, the global specialist in personalised medicine and clinical diagnostics has announced the completion of an evaluation of a commercial PCR test, its MycAssayTM Aspergillus assay, to detect invasive Aspergillosis (IA) in a mixed population of 158 patients with underlying haematological or critical illness. The prospective evaluation was per...
Commentary: Glybera- When the experts disagree
Published with kind permission of MEDNOUS. The Committee for Advanced Therapies (CAT) was set up at the European Medicines Agency in 2009 in order to give expert advice on whether advanced therapy medicinal products should be approved or not. These therapies include gene and cell therapies and products engineered from human and/or animal tissue. The [...]
Prosensa named Most Innovative European Biotech SME - Company wins prestigious EuropaBio Award
Leiden, The Netherlands, 8 November 2011 – Prosensa, the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, has won EuropaBio’s Most Innovative European Biotech SME Award 2011, presented at a ceremony in Brussels earlier today. The award comes with prize money of €10,000 and two years’ membership of EuropaBio. The EuropaBio Awar...
DOCTORS.NET.UK teams up with CANCER RESEARCH UK to run educational campaign for GPS
November 8th 2011: Cancer Research UK has appointed Doctors.net.uk - the largest and most active professional network of doctors in the UK – to run an educational campaign for GPs which is supportive of the charity’s key goals. Cancer Research UK, which is Europe’s biggest funder of cancer research, will provide educational support for GPs on two of its major...
Capital Increase: AFFiRiS Brings Santo VC and MIG 11 on Board
Vienna, November 8, 2011 – Santo VC GmbH has acquired a EUR 20 million stake in Vienna-based AFFiRiS AG effective immediately and has also secured an option for further capital increases in the future. At the same time, the German MIG fund increased its existing investment in AFFiRiS by EUR 5 million through its MIG 11 fund. As a result, AFFiRiS now has an additional EUR 25 million in e...
How Facebook is helping bridge the digital divide in patient recruitment February 15, 2011 - Philadelphia, PA – With its rapidly expanding capacity and diversified user base, Facebook has developed technology that helps clinical trial recruiters to precisely target populations and reaches them in a way that was never before possible. Working closely with Facebook, MediciGl...
8th November 2011: The NHS Technology Adoption Centre, NTAC, has launched a new online tool which has been designed to enable proven medical technology to be more efficiently adopted into the NHS. The Generic Adoption Process, or GAP, provides a clear and detailed roadmap, along with the required tools to enable proven medical technologies to be adopted. The unique tool is aimed at both...
AmpliPhi Biosciences Appoints Philip J. Young as President and CEO
8 November 2011, SEATTLE, Wa. & COLWORTH, UK - AmpliPhi Biosciences Corporation (APHB.PK), a leader in the development of bacteriophage-based anti-bacterial therapies, has announced the appointment of Philip J. Young as President and Chief Executive Officer (CEO). Mr. Young, who is based in the US, is a long time executive in the biopharmaceuticals industry. He is the former presi...
20,000-molecule Maybridge collection will help identify compound candidates to treat a wide range of diseases TINTAGEL, England (October 18, 2011) – Thermo Fisher Scientific Inc., the world leader in serving science, today announced that the Moulder Center for Drug Discovery Research at Temple University’s School of Pharmacy has selected the company’s Maybridge screening l...
Preventing and treating diabetic hypoglycemia associated with exercise: the forgotten problem
Regular exercise is recommended for people with type 1 and 2 diabetes, but it can increase the risk of hypoglycemia. In the latest issue of Diabetic Hypoglycemia (www.hypodiab.com), Younk and colleagues discuss the topic of hypoglycemia risk during exercise in people with diabetes and behavioral strategies for reducing this risk,1 such as ingesting carbohydrate before, during and/or after exe...
BD launches a new generation of disposable auto-injectors
BD Physioject™ provides an innovative solution with proven* patient acceptance, ease of use and robust system functionality Location (08 November 2011) – BD Medical, a segment of BD (Becton, Dickinson and Company), announced today the launch of the BD Physioject™ disposable auto-injector. This clinically proven,* reliable and cost-effective system is sp...
Data from ECLIPSE II HCV study shows four weeks of IL-7 (CYT107) added to Peginterferon and Ribavirin (SOC) induces a broad immune response associated with HCV viral elimination in genotype one and four treatment experienced patients defined as non-responders to SOC Paris, November 8, 2011 - Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new t...
